High Level Indicators

90% reduction in the number of TB deaths by 2030* Estimated data	Baseline 2015 24,900	Milestone 2020 16,200	Target 2030 2,500

80% reduction in TB incidence rate by 2030* Estimate x 100,000 pop.	Baseline 2015 27.5	Milestone 2020 22	Target 2030 5.5

Estimated TB Deaths in the Americas: Trend, Milestones, and Targets

Estimated TB incidence in the Americas: Trend, Milestones, and Targets

TB-affected households that face catastrophic costs due to TB (%)	Baseline 2015 NA**	Milestone 2020 Zero	Target 2030 Zero

* Compared to 2015
** Not available

Countries with high TB estimated burden* the Americas, 2019

Country	Number of estimated cases	% of total estimated cases	Estimated incidence (x 100,000 population)
Brazil	96,000	33.1%	45.5
Peru	39,000	13.4%	120.0
México	30,000	10.3%	23.5
Colombia	19,000	6.6%	35.8
Haiti	18,000	6.2%	168.7
Argentina	13,000	4.5%	29.0
Venezuela	13,000	4.5%	45.6
Bolivia	12,000	4.1%	104.2
Ecuador	7,900	2.7%	45.5
El Salvador	3,800	1.3%	58.9
Paraguay	3,300	1.1%	46.8
Guyana	620	0.2%	79.2
Total	255,620	88%	46.5
Total region	290,000	100%	28.7

*Countries with more than 10,000 cases and countries with an incidence rate > 45 per 100,000 population.

- 12 countries have a high TB estimated burden with an incidence rate more than 45 per 100,000 population. They represent 88% of the cases in the Region.

- In 2019, the TB case detection gap in the Region was 52,500 cases.

- In the last 5 years, the incidence rate has increased. To achieve 2020 Milestone of the End TB Strategy targets, there must be a 23% annual decline.

- Countries in the Region must conduct surveys on the catastrophic costs incurred by affected households.

End TB Strategy - Priority Indicators

INDICATOR		2019 FIGURES	2025 TARGET
TB treatment coverage*		81%	≥ 90%
Treatment success rate	New and Relapsed (2018)	76%	≥ 90%
	RR/MDR (2017)	59%	
Percentage of TB-affected households that face catastrophic costs due to TB		NA**	0%
Percentage of new TB patients diagnosed using WHO-recommended rapid tests		25%	≥ 90%
Latent TB infection treatment coverage	Children under 5	61%	≥ 90%
	HIV	26%	≥ 90%
Contact investigation coverage		70%	≥ 90%
TB patients with drug-susceptibility testing (DST) results		38%	100%
New TB drug treatment coverage		NA**	≥ 90%
Percentage of TB patients who know their HIV status		80%	100%
TB case fatality rate***		8%	≤ 5%

* Calculated based on the estimated number of incident cases
** Not available

Recommendations to accelerate progress toward ending TB in the Americas:

1. Improve and/or accelerate the implementation and expansion of early diagnosis with the new rapid molecular tests.
2. Increase TB case finding and contact tracing.
3. Guarantee TB preventive treatment, especially in children less than 15 years old and in people with HIV.
4. Accelerate the implementation of the new oral MDR-TB regimens and the introduction of dispersible pediatric drugs.
5. Strengthen the interventions with vulnerable populations and on TB social determinants through interprogrammatic and intersectoral people- and community-centered activities.
6. Promote special approaches such as the TB Control in Large Cities Initiative, the Parliamentary Front against TB, and the expansion of operational research.
7. Fill the existing financial gaps, reducing dependence on external funding, to guarantee sustainability.
8. Implement the multisectoral accountability framework for TB (MAF-TB) to facilitate reaching the international targets and commitments.

www.paho.org/tuberculosis